Pensionfund Dsm Netherlands Raised Sabra Health Care Reit (SBRA) Stake By $2.04 Million; Dicerna Pharmaceuticals (DRNA) SI Increased By 23.45%

Pensionfund Dsm Netherlands increased Sabra Health Care Reit Inc (SBRA) stake by 191.97% reported in 2017Q3 SEC filing. Pensionfund Dsm Netherlands acquired 97,330 shares as Sabra Health Care Reit Inc (SBRA)’s stock declined 4.90%. The Pensionfund Dsm Netherlands holds 148,030 shares with $3.25M value, up from 50,700 last quarter. Sabra Health Care Reit Inc now has $3.18B valuation. The stock decreased 2.03% or $0.37 during the last trading session, reaching $17.83. About 1.52M shares traded. Sabra Health Care REIT, Inc. (NASDAQ:SBRA) has risen 23.68% since January 15, 2017 and is uptrending. It has outperformed by 6.98% the S&P500.

Dicerna Pharmaceuticals Incorporated (NASDAQ:DRNA) had an increase of 23.45% in short interest. DRNA’s SI was 458,500 shares in January as released by FINRA. Its up 23.45% from 371,400 shares previously. With 240,700 avg volume, 2 days are for Dicerna Pharmaceuticals Incorporated (NASDAQ:DRNA)’s short sellers to cover DRNA’s short positions. The SI to Dicerna Pharmaceuticals Incorporated’s float is 3.66%. The stock decreased 0.12% or $0.01 during the last trading session, reaching $8.42. About 132,779 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has declined 5.22% since January 15, 2017 and is downtrending. It has underperformed by 21.92% the S&P500.

Among 14 analysts covering Sabra Health Care REIT (NASDAQ:SBRA), 6 have Buy rating, 2 Sell and 6 Hold. Therefore 43% are positive. Sabra Health Care REIT has $32 highest and $20.0 lowest target. $24.17’s average target is 35.56% above currents $17.83 stock price. Sabra Health Care REIT had 45 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Sabra Health Care REIT, Inc. (NASDAQ:SBRA) earned “Neutral” rating by SunTrust on Wednesday, November 11. Mizuho downgraded Sabra Health Care REIT, Inc. (NASDAQ:SBRA) on Monday, July 10 to “Underperform” rating. RBC Capital Markets downgraded Sabra Health Care REIT, Inc. (NASDAQ:SBRA) rating on Monday, November 2. RBC Capital Markets has “Underperform” rating and $26 target. The rating was maintained by Barclays Capital with “Overweight” on Wednesday, November 11. As per Monday, October 23, the company rating was maintained by Jefferies. The stock of Sabra Health Care REIT, Inc. (NASDAQ:SBRA) has “Buy” rating given on Thursday, November 12 by Mizuho. RBC Capital Markets downgraded Sabra Health Care REIT, Inc. (NASDAQ:SBRA) on Thursday, September 24 to “Sector Perform” rating. The firm has “Buy” rating by Suntrust Robinson given on Wednesday, June 1. As per Monday, June 12, the company rating was maintained by Cantor Fitzgerald. As per Tuesday, September 26, the company rating was maintained by Jefferies.

Pensionfund Dsm Netherlands decreased Stag Industrial Inc (NYSE:STAG) stake by 17,000 shares to 63,500 valued at $1.74M in 2017Q3. It also reduced Infrareit Inc stake by 42,000 shares and now owns 45,180 shares. Eastgroup Properties Inc (NYSE:EGP) was reduced too.

Investors sentiment increased to 5.24 in 2017 Q3. Its up 3.43, from 1.81 in 2017Q2. It is positive, as 26 investors sold SBRA shares while 23 reduced holdings. 133 funds opened positions while 124 raised stakes. 297.15 million shares or 307.35% more from 72.95 million shares in 2017Q2 were reported. Balyasny Asset Mngmt Llc stated it has 480,896 shares. Covington invested in 0% or 2,500 shares. Advantus has invested 0.13% of its portfolio in Sabra Health Care REIT, Inc. (NASDAQ:SBRA). Oakworth Cap Inc owns 244 shares for 0% of their portfolio. Lazard Asset Mgmt Ltd Liability Corporation owns 10,638 shares for 0% of their portfolio. River Road Asset Mgmt Ltd Liability Co holds 0.97% in Sabra Health Care REIT, Inc. (NASDAQ:SBRA) or 2.26 million shares. Moreover, State Of New Jersey Common Pension Fund D has 0.03% invested in Sabra Health Care REIT, Inc. (NASDAQ:SBRA) for 299,500 shares. Orinda Asset Mngmt Ltd Liability holds 74,377 shares or 1.5% of its portfolio. Thrivent Financial For Lutherans has invested 0.01% of its portfolio in Sabra Health Care REIT, Inc. (NASDAQ:SBRA). Dimensional Fund Advisors LP reported 2.41 million shares. Loomis Sayles And Ltd Partnership has 328,797 shares. Natixis reported 0.01% in Sabra Health Care REIT, Inc. (NASDAQ:SBRA). Tower Rech Ltd Liability Co (Trc) owns 6,763 shares for 0.01% of their portfolio. Louisiana State Employees Retirement stated it has 0.05% of its portfolio in Sabra Health Care REIT, Inc. (NASDAQ:SBRA). American Century reported 638,109 shares.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $434.82 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

Since December 18, 2017, it had 1 buy, and 0 sales for $2.00 million activity. Bain Capital Life Sciences Investors – LLC also bought $2.00M worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares.

Among 5 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dicerna Pharmaceuticals has $30 highest and $3.50 lowest target. $9.88’s average target is 17.34% above currents $8.42 stock price. Dicerna Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) rating on Tuesday, May 10. Stifel Nicolaus has “Buy” rating and $16 target. H.C. Wainwright maintained the stock with “Buy” rating in Friday, August 11 report. The firm earned “Buy” rating on Tuesday, July 18 by Cowen & Co. The rating was maintained by Stifel Nicolaus on Monday, August 10 with “Buy”. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Neutral” rating given on Monday, August 15 by Chardan Capital Markets. As per Thursday, November 2, the company rating was maintained by Stifel Nicolaus. The firm earned “Mkt Perform” rating on Tuesday, January 31 by Leerink Swann. Chardan Capital Markets maintained the stock with “Neutral” rating in Thursday, June 30 report. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Outperform” rating given on Tuesday, September 8 by Cowen & Co. The rating was initiated by H.C. Wainwright on Monday, December 12 with “Buy”.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: